Ken Griffin Synthetic Biologics, Inc. Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.3 - $4.3 $639,459 - $1.2 Million	-278,026 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.5 $632,658 - $1.05 Million	234,318 Added 536.1%	278,026 $750,000
Q3 2021 Nov 15, 2021	BUY	$4.3 - $5.8 $142,437 - $192,125	33,125 Added 313.0%	43,708 $20,000
Q2 2021 Aug 16, 2021	SELL	$4.6 - $7.2 $2.43 Million - $3.81 Million	-528,540 Reduced 98.04%	10,583 $63,000
Q1 2021 May 17, 2021	BUY	$5.0 - $11.7 $2.7 Million - $6.31 Million	539,123 New	539,123 $368,000
Q2 2019 Aug 14, 2019	SELL	$4.9 - $6.6 $124,807 - $168,108	-25,471 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$5.9 - $8.1 $69,077 - $94,834	11,708 Added 85.07%	25,471 $0
Q4 2018 Feb 14, 2019	BUY	$5.2 - $26.8 $71,567 - $368,848	13,763 New	13,763 $77,000

Ticker SYN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,844,100
Market Cap $9.51M
Description
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.